Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $32.4 million.

  • Crinetics Pharmaceuticals' Accumulated Expenses rose 2369.9% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 2369.9%. This contributed to the annual value of $28.9 million for FY2024, which is 9898.74% up from last year.
  • Crinetics Pharmaceuticals' Accumulated Expenses amounted to $32.4 million in Q3 2025, which was up 2369.9% from $21.8 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Accumulated Expenses peaked at $32.4 million during Q3 2025, and registered a low of $3.2 million during Q1 2021.
  • For the 5-year period, Crinetics Pharmaceuticals' Accumulated Expenses averaged around $13.1 million, with its median value being $9.1 million (2022).
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Accumulated Expenses soared by 13702.89% in 2024, and later soared by 697.42% in 2025.
  • Crinetics Pharmaceuticals' Accumulated Expenses (Quarter) stood at $6.6 million in 2021, then soared by 37.84% to $9.1 million in 2022, then surged by 59.86% to $14.5 million in 2023, then skyrocketed by 98.99% to $28.9 million in 2024, then grew by 12.15% to $32.4 million in 2025.
  • Its Accumulated Expenses was $32.4 million in Q3 2025, compared to $21.8 million in Q2 2025 and $16.6 million in Q1 2025.